This four-year ERC Horizon 2020 funded project (2020-2023), involves 13 institutions from 9 different countries and is led by the Hospices Civils de Lyon, France. It aims to develop a platform to collect, manage and analyse a large amount of data on health status and multidimensional quality of life (physical, mental and social wellbeing) of cancer patients after immune therapy treatment. This will provide insights for clinicians and policy makers to propose individualised monitoring strategies following immunotherapy treatment, in order to minimize risks for the patients and optimize their quality of life.
Our main involvement in this project is to lead the quantitative analyses required to understand the causal determinants of quality of life following immunotherapy treatment. More specifically, we will identify patterns of adverse events following immunotherapy and investigate how their occurrence impacts the different components of quality of life.
Principal Investigators: Clemence Leyrat and Bernard Rachet
Co-investigators: Camille Maringe, Manuela Quaresma and Sara Benitez Majano